Literature DB >> 15339672

No increase in age-specific incidence of myelodysplastic syndromes.

Ulrich Germing1, Corinna Strupp, Andrea Kündgen, David Bowen, Carlo Aul, Rainer Haas, Norbert Gattermann.   

Abstract

BACKGROUND AND OBJECTIVES: Epidemiological data on myelodysplastic syndromes (MDS) are sparse. However, the available evidence indicates that MDS is among the most common hematologic diseases. DESIGN AND METHODS: In a previous study, we showed that incidence rates rose from 1 to 4.1 in the period 1976-1990, with no increase between 1986 and 1990. We extended our study, covering the years 1991 through 2001. Diagnostic criteria and cytomorphology remained the same, consistently applying the criteria of the FAB classification.
RESULTS: Three-hundred and eight new cases of MDS were identified in the town district of Düsseldorf, which provides the reference population for calculating incidences. There was no further rise in MDS incidence. The crude incidence in the period 1991-2001 was 4.9 (5.52 in males, 4.36 in females), which is similar to that in the 1986-1990 period. Age specific incidences were 8.7, 24.5, and 31.3 for the age groups 60-70, 71-80, and 80-90, respectively. The incidence of MDS in the age group >70 years was significantly higher among males (42.3) than among females (19.0). The preponderance of males was found among patients with refractory anemia with excess blasts (16 vs 3), refractory anemia with excess blasts in transformation (7 vs 2), refractory anemia (15 vs 6) and chronic myelomonocytic leukemia (7 vs 2), whereas, somewhat surprisingly, the age-related incidences refractory anemia with ringed sideroblasts was similar for males and females (4 vs 5). The data on MDS incidence in the town district of Düsseldorf showed a plateau since 1986. INTERPRETATION AND
CONCLUSIONS: Interpreting our data covering a 26-year period, we feel that the increase in the early years primarily reflected improved case ascertainment, whereas our new data may provide a good approximation of the true incidence of MDS. There is no evidence that the age-adjusted incidence of MDS is rising.

Entities:  

Mesh:

Year:  2004        PMID: 15339672

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

1.  Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).

Authors:  Marc Maynadié; François Girodon; Ines Manivet-Janoray; Morgane Mounier; Francine Mugneret; François Bailly; Bernardine Favre; Denis Caillot; Tony Petrella; Michel Flesch; Paule-Marie Carli
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

3.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

4.  Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes.

Authors:  A R Levy; D Zou; N Risebrough; R Buckstein; T Kim; N Brereton
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

5.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors:  Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

Review 6.  Role of epigenetic therapy in myelodysplastic syndrome.

Authors:  Tapan M Kadia; Guillermo Garcia-Manero
Journal:  Expert Rev Hematol       Date:  2008-12       Impact factor: 2.929

7.  Platelet proteome analysis reveals integrin-dependent aggregation defects in patients with myelodysplastic syndromes.

Authors:  Julia Fröbel; Ron-Patrick Cadeddu; Sonja Hartwig; Ingmar Bruns; Christian M Wilk; Andrea Kündgen; Johannes C Fischer; Thomas Schroeder; Ulrich G Steidl; Ulrich Germing; Stefan Lehr; Rainer Haas; Akos Czibere
Journal:  Mol Cell Proteomics       Date:  2013-02-04       Impact factor: 5.911

Review 8.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

9.  Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.

Authors:  Annette Powers; Claudio Faria; Michael S Broder; Eunice Chang; Dasha Cherepanov
Journal:  Am Health Drug Benefits       Date:  2012-11

10.  Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.

Authors:  Matteo Giovanni Della Porta; Luca Malcovati
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.